Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
Engineering Research Center of Modern Preparation Technology of TCM, Ministry of Education, Shanghai, 201203, People's Republic of China.
Int J Nanomedicine. 2024 Jul 9;19:6895-6929. doi: 10.2147/IJN.S465959. eCollection 2024.
This review aimed to systematically investigate the intracellular and subcellular fate of various types of targeting carriers. Upon entering the body via intravenous injection or other routes, a targeting carrier that can deliver therapeutic agents initiates their journey. If administered intravenously, the carrier initially faces challenges presented by the blood circulation before reaching specific tissues and interacting with cells within the tissue. At the subcellular level, the car2rier undergoes processes, such as drug release, degradation, and metabolism, through specific pathways. While studies on the fate of 13 types of carriers have been relatively conclusive, these studies are incomplete and lack a comprehensive analysis. Furthermore, there are still carriers whose fate remains unclear, underscoring the need for continuous research. This study highlights the importance of comprehending the in vivo and intracellular fate of targeting carriers and provides valuable insights into the operational mechanisms of different carriers within the body. By doing so, researchers can effectively select appropriate carriers and enhance the successful clinical translation of new formulations.
本综述旨在系统地研究各种类型靶向载体的细胞内和亚细胞命运。通过静脉注射或其他途径进入体内后，能够递送治疗剂的靶向载体开始了它们的旅程。如果通过静脉内给药，载体在到达特定组织并与组织内的细胞相互作用之前，首先要面对血液循环带来的挑战。在亚细胞水平上，载体通过特定途径经历药物释放、降解和代谢等过程。虽然已经对 13 种载体的命运进行了相对明确的研究，但这些研究并不完整，缺乏全面的分析。此外，仍有一些载体的命运尚不清楚，这凸显了持续研究的必要性。本研究强调了理解靶向载体体内和细胞内命运的重要性，并为体内不同载体的作用机制提供了有价值的见解。通过这样做，研究人员可以有效地选择合适的载体，并提高新制剂成功临床转化的可能性。
